Rituximab maintenance therapy after autologous stem-cell transplantation in patients with relapsed CD20+ diffuse large B-cell lymphoma: Final analysis of the collaborative trial in relapsed aggressive lymphoma

Christian Gisselbrecht, Norbert Schmitz, Nicolas Mounier, Devinder Singh Gill, David C. Linch, Marek Trneny, Andre Bosly, Noel J. Milpied, John Radford, Nicolas Ketterer, Ofer Shpilberg, Ulrich Duḧrsen, Hans Hagberg, David D. Ma, Andreas Viardot, Ray Lowenthal, Josette Brier̀e, Gilles Salles, Craig H. Moskowitz, Bertram Glass

Research output: Contribution to journalArticlepeer-review

171 Scopus citations

Abstract

Purpose: The standard treatment for relapsed diffuse large B-cell lymphoma (DLBCL) is salvage chemotherapy followed by high-dose therapy and autologous stem-cell transplantation (ASCT). The impact of maintenance rituximab after ASCT is not known. Patients and Methods: In total, 477 patients with CD20 + DLBCL who were in their first relapse or refractory to initial therapy were randomly assigned to one of two salvage regimens. After three cycles of salvage chemotherapy, the responding patients received high-dose chemotherapy followed by ASCT. Then, 242 patients were randomly assigned to either rituximab every 2 months for 1 year or observation. Results: After ASCT, 122 patients received rituximab, and 120 patients were observed only. The median follow-up time was 44 months. The 4-year event-free survival (EFS) rates after ASCT were 52% and 53% for the rituximab and observation groups, respectively (P = .7). Treatment with rituximab was associated with a 15% attributable risk of serious adverse events after day 100, with more deaths (six deaths v three deaths in the observation arm). Several factors affected EFS after ASCT (P < .05), including relapsed disease within 12 months (EFS: 46% v 56% for relapsed disease after 12 months), secondary age-adjusted International Prognostic Index (saaIPI) more than 1 (EFS: 37% v 61% for saaIPI < 1), and prior treatment with rituximab (EFS: 47% v 59% for no prior rituximab). A significant difference in EFS between women (63%) and men (46%) was also observed in the rituximab group. In the Cox model for maintenance, the saaIPI was a significant prognostic factor (P < .001), as was male sex (P = .01). Conclusion: In relapsed DLBCL, we observed no difference between the control group and the rituximab maintenance group and do not recommend rituximab after ASCT.

Original languageEnglish (US)
Pages (from-to)4462-4469
Number of pages8
JournalJournal of Clinical Oncology
Volume30
Issue number36
DOIs
StatePublished - Dec 20 2012

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Rituximab maintenance therapy after autologous stem-cell transplantation in patients with relapsed CD20<sup>+</sup> diffuse large B-cell lymphoma: Final analysis of the collaborative trial in relapsed aggressive lymphoma'. Together they form a unique fingerprint.

Cite this